Results 51 to 60 of about 5,026 (202)

suPAR – A Future Prognostic Biomarker in Emergency Medicine [PDF]

The Journal of Emergency Medicine, 2015
Background Efficient triage in the Emergency Departments (ED) is important to identify patients in need of urgent care. Biomarker measurements may aid these clinical decisions. suPAR, soluble urokinase-type plasminogen activator receptor, is a non-specific biomarker reflecting inflammation and is a strong prognostic marker for several diseases.
Østervig, Rebecca M, Køber, Lars, Forberg, Jakob L, Rasmussen, Lars S, Eugen-Olsen, Jesper, Iversen, Kasper   +5 more
openaire   +1 more source

Hepatic suPAR formation.

, 2019
Hepatic suPAR formation.
Jan Nehlin (214365), Søren Møller (502423), Christian Mortensen (7325975), Ove Andersen (295030), Lise Hobolth (7325978), Emilie Garnæs (7325972)   +5 more
core   +1 more source

Seminal Biomarkers and Sperm Proteomic Signatures Differentiate Acute and Chronic Male Accessory Gland Inflammation

Andrology, EarlyView.
ABSTRACT Background Male accessory gland inflammation (MAGI) comprises a heterogeneous group of inflammatory conditions that may differentially affect the seminal microenvironment and sperm function. However, whether transrectal ultrasound (TRUS)‐defined MAGI phenotypes correspond to distinct biological profiles remains insufficiently characterized ...
Emanuela Teveroni, Fiorella Di Nicuolo, Giorgia Mazzuccato, Alessandro Oliva, Emanuele Pierpaolo Vodola, Francesca Mancini, Carla Di Nardo, Edoardo Vergani, Michela Cicchinelli, Federica Iavarone, Cassandra Serantoni, Giuseppe Maulucci, Alessia Riente, Alfredo Pontecorvi, Andrea Urbani, Domenico Milardi, Silvia Baroni   +16 more
wiley   +1 more source

Soluble urokinase plasminogen activator receptor: from biomarker to active participant in atherosclerosis and cardiovascular disease

The Journal of Clinical Investigation, 2022
Atherosclerosis contributes to the majority of deaths related to cardiovascular disease (CVD). Recently, the nonspecific inflammatory biomarker soluble urokinase plasminogen activator receptor (suPAR) has shown prognostic value in patients with CVD ...
Traci T. Goodchild, Zhen Li, David J. Lefer   +2 more
doaj   +1 more source

Beyond Traditional Screening: The Future of Heart Failure Detection With Biomarkers and AI

iNew Medicine, Volume 2, Issue 3, September 2026.
Advancing HF Screening: Integrating Technology and Risk Factors Across Eras. This diagram provides a comprehensive review of the historical developments and projected trends of heart failure (HF) screening methodologies, with the prevalent risk factors for HF depicted at the base.
Xiaofeng Fang, Yinbo Xu, Yiting Zhao, Liuyi Li, Zhengyi Cheng, Zhongqi Zhang, Yuhang Luo, Qiaoling Liu, Chen Gong, Shichun Shen   +9 more
wiley   +1 more source

Effects of Acute Exercise on Circulating Soluble Form of the Urokinase Receptor in Patients With Major Depressive Disorder

Biomarker Insights, 2017
Inflammation has been proposed to play a role in the generation of depressive symptoms. Previously, we demonstrated that patients with major depressive disorder (MDD) have increased plasma levels of the soluble form of the urokinase receptor (suPAR), a ...
Anna Gustafsson, Filip Ventorp, Anita GM Wisén, Lars Ohlsson, Lennart Ljunggren, Åsa Westrin   +5 more
doaj   +1 more source

Soluble urokinase plasminogen activator receptor (suPAR) predicts critical illness and kidney failure in patients admitted to the intensive care unit

Scientific Reports, 2021
Soluble urokinase plasminogen activator receptor (suPAR) is an inflammatory biomarker and risk factor for kidney diseases, with a potential prognostic value in critically ill patients.
Alexander C. Reisinger, Tobias Niedrist, Florian Posch, Stefan Hatzl, Gerald Hackl, Juergen Prattes, Gernot Schilcher, Anna-Maria Meißl, Reinhard B. Raggam, Markus Herrmann, Philipp Eller   +10 more
doaj   +1 more source

Serum Levels of Soluble Urokinase Plasminogen Activator Receptor Predict Tumor Response and Outcome to Immune Checkpoint Inhibitor Therapy

Frontiers in Oncology, 2021
BackgroundImmune checkpoint inhibitors (ICIs) have led to a paradigm shift in cancer therapy, improving outcomes in the treatment of various malignancies. However, not all patients benefit to the same extend from ICI.
Sven H. Loosen, Sven H. Loosen, Joao Gorgulho, Joao Gorgulho, Markus S. Jördens, Maximilian Schulze-Hagen, Fabian Beier, Mihael Vucur, Anne T. Schneider, Christiane Koppe, Alexander Mertens, Jakob N. Kather, Frank Tacke, Verena Keitel, Tim H. Brümmendorf, Christoph Roderburg, Christoph Roderburg, Tom Luedde   +17 more
doaj   +1 more source

The Landscape of Biomarkers in ICU‐Associated AKI: From Protein Markers to Cell‐Free Nucleic Acids

Journal of Clinical Laboratory Analysis, Volume 40, Issue 17, September 2026.
Acute kidney injury (AKI) in critically ill patients—particularly in sepsis—often develops early and is missed by creatinine/urine output–based criteria, delaying risk stratification and timely intervention. This review synthesizes current evidence on established and emerging AKI biomarkers (e.g., NGAL, KIM‐1, [TIMP‐2]·[IGFBP7]) alongside circulating ...
Qi Zhu, Feng Yang, Hua Zheng, Xinxin Guo, Zhijin Chen, Limin Chen, Daoli Wang, Jiaqi Wang, Xinmeng Wang, Zhiyuan Huang, Zhenhua Ji   +10 more
wiley   +1 more source

Admission diagnosis for each suPAR tertile.

, 2017
Admission diagnosis for each suPAR tertile.
Takahide Ito (495210), Yoshihiro Takeda (2413891), Shu-ichi Fujita (456246), Nobukazu Ishizaka (456250), Hideaki Morita (353346), Daichi Maeda (749664), Tomohiro Fujisaka (3704488), Suguru Tanaka (3155118)   +7 more
core   +1 more source